Clinical trials: Cancer of the Head and Neck
Head and Neck Cancer, Human Papilloma Virus
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination…
- Trial name
- NCT03162224
- Testing
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Recurrent Head and Neck Carcinoma
Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies how well stereotactic body radiation therapy with HyperArc software technology works in treating patients with head and neck cancer that has come back.
- Trial name
- NCT03892720
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Squamous Cell Carcinoma, Surgery
Surgical Treatment of Stage T3 Squamous Cell Carcinomas of the Scalp
This study examines tumor- en surgical characteristics of stage T3 cutaneous squamous cell carcinomas on the scalp, diagnosed between 2010 and 2018. Histological data and patient- and tumor characteristics were collected.
- Conditions
- Squamous Cell Carcinoma, Surgery, Cancer Head Neck
- Trial name
- NCT05987579
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Maastricht University Medical Center
Esophageal Squamous Cell Carcinoma
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
- Trial name
- NCT01822613
- Testing
- LJM716, BYL719, Paclitaxel
- Where
- 13 sites in United States, Belgium and 7 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer, Lung Cancer
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
Primary Objectives: 1. To examine the effect of celecoxib treatment on histological response, markers of proliferation (Ki-67), and apoptosis. Secondary endpoints include time to second primary or recurrence and survival. 2.
- Trial name
- NCT00527982
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy
The purpose of this study is to determine the safety and efficacy of the side-to-side stapled intrathoracic esophagogastric anastomosis in Ivor-Lewis Oesophagectomy.
- Trial name
- NCT01242124
- Testing
- side-to-side stapled esophagogastric anastomosis, circular-stapled esophagogastric anastomosis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Squamous Cell Carcinoma, Circulating Tumor Cell
PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT
Head and neck squamous cell carcinoma (HNSCC) is the 4th highest incidence of cancer and 6th of cancer death of the males in Taiwan.
- Trial name
- NCT05008796
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Esophageal Neoplasms
Feasibility Study of Fiducial Markers in Oesophageal Cancer
Currently, patients of suitable fitness with non-metastatic esophageal cancer are treated with surgery, radiotherapy or chemoradiotherapy.
- Trial name
- NCT02403050
- Testing
- Fiducial markers
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- NHS Greater Glasgow and Clyde
Nasopharyngeal Neoplasms, Radiodermatitis
Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). Although intensity modulated radiation therapy (IMRT) has been widely used in China nowadays, radiation dermatitis is still common.
- Trial name
- NCT02729324
- Testing
- Medical Radiation Protectants (FORRAD®), Trolamine (Biafine)
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Yun-fei Xia
Advanced Solid Tumor
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05231746
- Testing
- hSTC810
- Where
- 5 sites in United States, South Korea
- Volunteers
- 47 people
- Sponsor
- STCube, Inc.
Breast Cancer, Head and Neck Cancer (H&N)
Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors
Urokinase plasminogen activator receptor (uPAR), the cell-surface receptor for its ligand uPA, plays a critical role in regulating cell migration and invasion-key drivers of cancer progression.
- Conditions
- Breast Cancer, Head and Neck Cancer (H&N), Pancreatic Cancer, Glioma
- Trial name
- NCT07639970
- Testing
- [⁶⁸Ga]Ga-HT547 and [¹⁷⁷Lu]Lu-HT547
- Volunteers
- 20 people
- Sponsor
- Hua Pang
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Esophageal Squamous Cell Carcinoma
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable…
- Trial name
- NCT06022861
- Testing
- LY01015, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Head and Neck Cancer, Recurrent Cancer
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistance.
- Trial name
- NCT06103617
- Testing
- Penicillamine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Esophageal Cancer
Chemoradiotherapy for Advanced Esophageal Cancer
This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with…
- Trial name
- PaRCUS (NCT02297217)
- Testing
- Carboplatin and Taxol (paclitaxel), External Beam Radiation
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- AHS Cancer Control Alberta
Squamous Cell Carcinoma of the Head and Neck
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC) patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be resistant to standard Radiation Therapy…
- Trial name
- NCT02031250
- Testing
- Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation Therapy)
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- University of Michigan Rogel Cancer Center
Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers
AF CRT +/- Nimorazole in HNSCC
The drug nimorazole belongs to a class of chemicals known as 5-nitroimidazoles. Drugs from this class are used against infection. In addition, nimorazole makes tumor cells more sensitive to radiotherapy.
- Trial name
- NCT01880359
- Testing
- Cisplatin, Radiotherapy, Nimorazole
- Where
- 19 sites in Australia, Belgium and 5 more
- Volunteers
- 640 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cutaneous Squamous Cell Carcinoma
Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck
The goal of this clinical trial is to learn if the combination of the drug cemiplimab along with a short course of radiation therapy called Quad Shot can be successfully given in several rounds to elderly or frail patients with…
- Trial name
- NCT07869823
- Testing
- Cemiplimab, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
Phase I Trial: T4 Immunotherapy of Head and Neck Cancer
The overall goal of this study is to investigate the safety of T4 immunotherapy when administered to treat loco-regional disease in Squamous Cell Cancer of the Head and Neck (SCCHN) that is not suitable for conventional active…
- Trial name
- NCT01818323
- Testing
- Intra-tumoral T4 immunotherapy
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.